D. Facklam

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

David W. Denning, Kieren A. Marr, W. Lau et al. · Journal of Infection · 2006 · 294 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

Nita L. Seibel, Cindy L. Schwartz, Antonio Arrieta et al. · Antimicrobial Agents and Chemotherapy · 2005 · 246 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

Luis Ostrosky‐Zeichner, D. P. Kontoyiannis, John Raffalli et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2005 · 189 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

J. Hiemenz, Pablo J. Cagnoni, David Simpson et al. · Antimicrobial Agents and Chemotherapy · 2005 · 150 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis

Dimitrios P. Kontoyiannis, V. Ratanatharathorn, Jo‐Anne H. Young et al. · Transplant Infectious Disease · 2008 · 111 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17